Yonghui Fu

Yonghui Fu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
WHWenfeng He
Wenfeng He
YZYue Zhou
Yue Zhou
JMJianyoung Ma
Jianyoung Ma
BWBo Wei
Bo Wei
YFYonghui Fu
Yonghui Fu

1 January 2020 in Bioengineered
Verified
Journal Article
Open access
YJYoukun Jie
Youkun Jie
LYLu Ye
Lu Ye
HCHe Chen
He Chen
XYXiaohong Yu
Xiaohong Yu
LCLi Cai
Li Cai
YFYonghui Fu
Yonghui Fu
Previous studies indicated that long non-coding RNAs (LncRNAs) were involved in the progression of multiple cancers including ovarian cancer (OV). LncRNA ELFN1-AS1 functioned as an oncogene in many cancers, but its potential roles in OV were largely unclear. In the current study, we were aimed at clarifying the biological roles and molecular mechanisms of ELFN1-AS1 in OV. We found that ELFN1-AS1 was significantly upregulated in OV tissues and cell lines. High expression of ELFN1-AS1 was associated with poor prognosis in OV patients. Knockdown of ELFN1-AS1 inhibited the proliferation, migration and invasion of SKOV3 cell lines and repressed tumor growth in xenografted ovarian models. Mechanistically, ELFN1-AS1 promoted the proliferation, migration and invasion of SKOV3 cells by sponging miR-497-3p. Additionally, CLDN4 was verified to be the target of miR-497-3p. Rescue experiments revealed that miR-497-3p inhibition could partly reverse the inhibitory effect of ELFN1-AS1 silencing on proliferation, migration and invasion of SKOV3 cell lines. Taken together, our findings indicated that ELFN1-AS1 acted as an oncogene in ovarian cancer through regulating the expression of CLDN4 by directly interacting with miR-497-3p. The results suggested that ELFN1-AS1 might act as a promising therapeutic target for OV. Graphical abstract